IL2 and systemic lupus erythematosus: The other study was the first randomized, double-blind, placebo-controlled, single-center phase 2 trial.[49] Sixty patients with active SLE were randomly assigned in a 1: 1 ratio to receive either three cycles of low-dose IL-2 therapy or placebo on top of standard-of-care therapy.